Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

Inclusion Criteria:

1. All subjects must personally sign and date the consent form before initiating anystudy specific procedures or activities;

2. All subjects must be able to comply with all the scheduled procedures in the study;

3. HLA_A2 genotype and gp100 positive malignant melanoma： Ⅳ stage or relapsed aftersurgery or chemotherapy or no available standard therapy;

4. At least one measurable lesion per RECIST V1.1;

5. Aged 18 to 69 years;

6. Expected survival ≥12 weeks; Eastern cooperative oncology group (ECOG) performancestatus of≤2;

7. Systematic usage of immunosuppressive drug or corticosteroid must have been stoppedfor more than 4 weeks;

8. All other treatment induced adverse events must have been resolved to ≤grade 1;

9. Laboratory tests must fulfill the following criteria: ANC ≥ 1000/uL, HGB>70g/L,Platelet count ≥ 50,000/uL, Creatinine clearance ≤1.5 ULN, Serum ALT/AST ≤2.5 ULN,Total bilirubin ≤1.5 ULN (except in subjects with Gilbert's syndrome);

Exclusion Criteria:

1. Presence of fungal, bacterial, viral, or other infection that is uncontrolled orrequiring iv antimicrobials for management. (Simple UTI and uncomplicated bacterialpharyngitis are permitted if responding to active treatment);

2. Patients with symptomatic central nervous system metastasis, intracranial metastasis,and cancer cells found in cerebrospinal fluid are not recommended to participate inthis study. Symptom free or post-treatment stable disease or disappearance of lesionsshould not be excluded. The specific selection is ultimately determined by theinvestigator;

3. Lactating women or women of childbearing age who plan to conceive during the timeperiod;

4. Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCVpositive);

5. Known history of infection with HIV;

6. Subjects need systematic usage of corticosteroid;

7. Subjects need systematic usage of immunosuppressive drug;

8. Planed operation, history of other related disease, or any other related laboratorytests restrict patients for the study;

9. Other reasons the investigator consider the patient may not be suitable for the study.